Table 4 Comparison of clinicopathological parameters against TRF2, Bcl-xL and p53 expressions
From: Expression of TRF2 and its prognostic relevance in advanced stage cervical cancer patients
TRF2 expression (n) OS (5 year,%) | Bcl-xL expression (n) OS (5 year,%) | p53 expression (n) OS (5 year,%) | ||||
|---|---|---|---|---|---|---|
Stage (n) | High | Low | High | Low | High | Low |
IIB (7) | 5 | 2 | 2 | 5 | 3 | 4 |
n.d. | 50 | n.d. | 80 | 66.7 | n.d. | |
IIIB-IVA (13) | 8 | 5 | 9 | 4 | 6 | 7 |
50 | 20 | 11 | n.d. | 16.7 | 57.1 | |
P log rank | 0.04* | 0,006* | 0,01* | |||
Histologic grade (n) | ||||||
High grade (12) | 7 | 5 | 7 | 5 | 5 | 7 |
42 | 20 | 28** | 80 | 40** | 57.1 | |
Low grade (8) | 6 | 2 | 4 | 4 | 4 | 4 |
83 | 50 | 75 | n.d. | 75 | n.d. | |
P log rank | 0,14 | 0,01* | 0,01* | |||